GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Cash Conversion Cycle

MedMira (MedMira) Cash Conversion Cycle : -2,576.91 (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

MedMira's Days Sales Outstanding for the three months ended in Jan. 2024 was 813.03.
MedMira's Days Inventory for the three months ended in Jan. 2024 was 217.48.
MedMira's Days Payable for the three months ended in Jan. 2024 was 3607.42.
Therefore, MedMira's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2024 was -2,576.91.


MedMira Cash Conversion Cycle Historical Data

The historical data trend for MedMira's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Cash Conversion Cycle Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,946.44 -2,336.68 -1,781.19 -947.14 -6,704.56

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,189.71 -4,052.03 3,421.88 -5,080.13 -2,576.91

Competitive Comparison of MedMira's Cash Conversion Cycle

For the Biotechnology subindustry, MedMira's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where MedMira's Cash Conversion Cycle falls into.



MedMira Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

MedMira's Cash Conversion Cycle for the fiscal year that ended in Jul. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=1068.85+531.24-8304.65
=-6,704.56

MedMira's Cash Conversion Cycle for the quarter that ended in Jan. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=813.03+217.48-3607.42
=-2,576.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


MedMira Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of MedMira's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Introduces VYRA TriDemic

By ACCESSWIRE ACCESSWIRE 12-30-2022

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019